Your browser doesn't support javascript.
The epidemiology of oral cancer during the COVID-19 pandemic in Northern Italy: Incidence, survival, prevalence.
Mangone, Lucia; Mancuso, Pamela; Bisceglia, Isabella; Setti, Giacomo; Malaguti, Giuliano; Giorgi Rossi, Paolo.
  • Mangone L; Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Mancuso P; Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Bisceglia I; Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Setti G; Centro Universitario Odontoiatria, University of Parma, Parma, Italy.
  • Malaguti G; Department of Specialist Surgeries Head-Neck, Modena and Reggio Emilia University, Modena, Italy.
  • Giorgi Rossi P; Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Front Oral Health ; 3: 982584, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-20239216
ABSTRACT
Despite novel treatment approaches, oral cancer survival has not improved significantly and the disease often presents a disabling path for patients. The aim of this work was to describe the epidemiological data of oral cancers in a province of northern Italy. Incident cases in the period 1996-2020 and EU population standardized rates were reported for Oral Cavity cancer (OC) and OroPharyngeal cancer (OP). Annual percent changes (APC) were estimated with joint point analysis. The 5-year survival was calculated in three different periods 1996-2000, 2001-2010 and 2011-2015. From 1996 to 2020, 771 cases of oral cancers (442 OC and 329 OP) were recorded with the age-standardized incidence rate 7.28 (10.74 in males and 3.97 in females) 3.82 for OC and 3.47 for OP. In males there is a significant increase in the incidence of OP up to 2017 (APC 11; 95% CI, 4.9-17.5), which then decreases; in females the rates are constant. In 2020 (the era of Covid-19), we did not see a decline in incidence compared to 2019. The 5-year survival (for cases diagnosed in 2011-2015) was 55.6%, 56.5% and 56% for OC, OP and OC + OP, respectively; it was somewhat higher in females and was undergoing some changes over the course of years. The number of prevalent cases as of 1 January 2021 is 314 (175 OC, 139 OP). The study showed a decline in cancers in men, particularly for OP; survival shows improvement in the long-term examined; Covid-19 had no negative impact on 2020 diagnoses.
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio observacional / Estudio pronóstico Tópicos: Covid persistente Idioma: Inglés Revista: Front Oral Health Año: 2022 Tipo del documento: Artículo País de afiliación: Froh.2022.982584

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio observacional / Estudio pronóstico Tópicos: Covid persistente Idioma: Inglés Revista: Front Oral Health Año: 2022 Tipo del documento: Artículo País de afiliación: Froh.2022.982584